Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher R Smith

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Annals of Hematology|March 10, 2025
Sickle cell disease and opioid overdose outcomes in the United States: a nationwide analysisAnna L Bode, Oscar F Borja-Montes, Mohammed A Quazi, et al.
Journal of Medicinal Chemistry|June 19, 2015
Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine KinaseChristopher R Smith, Douglas R Dougan, Mallareddy Komandla, et al.
The Journal of Organic Chemistry|July 29, 2024
Zirconium Hydride Catalysis Initiated by Tetrabutylammonium FluorideAthenea N Aloiau, Briana M Bobek, Kelly E Pearson, et al.
The Journal of Organic Chemistry|February 29, 2024
Stereoselective Amine Synthesis Mediated by a Zirconocene Hydride to Accelerate a Drug Discovery ProgramAthenea N Aloiau, Briana M Bobek, Kersti Caddell Haatveit, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2015
Fragment-based drug discovery of potent and selective MKK3/6 inhibitorsMark Adams, Toshitake Kobayashi, J David Lawson, et al.
Journal of Medicinal Chemistry|August 27, 2021
Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (<i>S</i>)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3<i>H</i>-1,2,4-triazol-3-one, by Fragment-Based Drug DesignMark Sabat, Douglas R Dougan, Beverly Knight, et al.
RSC Medicinal Chemistry|December 22, 2022
Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hitsChristopher R Smith, Svitlana Kulyk, Misbha Ud Din Ahmad, et al.
Bioorganic & Medicinal Chemistry|August 4, 2022
Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitorsChristopher R Smith, Ruth Aranda, James G Christensen, et al.
Journal of Proteome Research|May 30, 2012
Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategiesAmol Prakash, Taha Rezai, Bryan Krastins, et al.
Journal of Medicinal Chemistry|December 29, 2023
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray CocrystallographyChristopher R Smith, Dan Chen, James G Christensen, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Annals of Hematology|March 10, 2025
Sickle cell disease and opioid overdose outcomes in the United States: a nationwide analysisAnna L Bode, Oscar F Borja-Montes, Mohammed A Quazi, et al.
Journal of Medicinal Chemistry|June 19, 2015
Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine KinaseChristopher R Smith, Douglas R Dougan, Mallareddy Komandla, et al.
The Journal of Organic Chemistry|July 29, 2024
Zirconium Hydride Catalysis Initiated by Tetrabutylammonium FluorideAthenea N Aloiau, Briana M Bobek, Kelly E Pearson, et al.
The Journal of Organic Chemistry|February 29, 2024
Stereoselective Amine Synthesis Mediated by a Zirconocene Hydride to Accelerate a Drug Discovery ProgramAthenea N Aloiau, Briana M Bobek, Kersti Caddell Haatveit, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2015
Fragment-based drug discovery of potent and selective MKK3/6 inhibitorsMark Adams, Toshitake Kobayashi, J David Lawson, et al.
Journal of Medicinal Chemistry|August 27, 2021
Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (<i>S</i>)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3<i>H</i>-1,2,4-triazol-3-one, by Fragment-Based Drug DesignMark Sabat, Douglas R Dougan, Beverly Knight, et al.
RSC Medicinal Chemistry|December 22, 2022
Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hitsChristopher R Smith, Svitlana Kulyk, Misbha Ud Din Ahmad, et al.
Bioorganic & Medicinal Chemistry|August 4, 2022
Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitorsChristopher R Smith, Ruth Aranda, James G Christensen, et al.
Journal of Proteome Research|May 30, 2012
Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategiesAmol Prakash, Taha Rezai, Bryan Krastins, et al.
Journal of Medicinal Chemistry|December 29, 2023
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray CocrystallographyChristopher R Smith, Dan Chen, James G Christensen, et al.
Pageof 5